Virax Biolabs Group Ratios and Metrics

Market cap in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 10, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Market Cap	3	5	2	11	-	-
Market Cap Growth	-22.85%	168.21%	-82.93%	-	-	-
Enterprise Value	0.85	0.81	-1.8	1.38	0	0
Last Close Price	0.17	1.14	0.72	6.95	-	-
PS Ratio	1255.72	781.84	11.80	1262.87	-	-
PB Ratio	0.23	0.87	0.34	1.18	-	-
P/TBV Ratio	0.15	0.75	0.27	0.81	-	-
EV/Sales Ratio	284.57	128.09	-11.48	161.52	-	-
EV/EBITDA Ratio	-	-	0.28	-	-	-
EV/EBIT Ratio	-	-	0.28	-	-	-
EV/FCF Ratio	-	-	0.25	-	-	-
Debt / Equity Ratio	0.09	0.06	0.03	0.02	0	0
Net Debt / Equity Ratio	-0.53	-0.68	-0.63	-1.01	0.02	0.03
Net Debt / EBITDA Ratio	0.51	0.65	0.52	1.61	0.01	0.03
Net Debt / FCF Ratio	0.48	0.75	0.47	2.20	0.03	0.03
Asset Turnover	0.00	0.00	0.02	0.00	0	3.98
Inventory Turnover	0.65	0.77	3.51	0.95	0	12.65
Quick Ratio	9.63	6.33	22.55	10.30	0.02	0.02
Current Ratio	11.35	7.27	25.94	10.61	0.04	0.05
Return on Equity (ROE)	-107.33%	-114.47%	-95.98%	-141.63%	172.53%	65.75%
Return on Assets (ROA)	-92.22%	-101.20%	-84.94%	-116.27%	-3925.59%	-2071.47%
Return on Invested Capital (ROIC)	-288.23%	-355.32%	-608.08%	-3127.01%	-46133.00%	-17148.80%
Return on Capital Employed (ROCE)	-105.73%	-111.36%	-91.38%	-148.76%	170.93%	62.98%
Buyback Yield / Dilution	-70.75%	-85.92%	-88.75%	-11.15%	-504.72%	-154.71%
Total Shareholder Return	-70.75%	-85.92%	-88.75%	-11.15%	-504.72%	-154.71%

SEC Filings: 10-K · 10-Q